ALLK - Allakos's lirentelimab data published in New England Journal of Medicine

Allakos ([[ALLK]] +7.9%) has announced the publication of results from Phase 2 study of lirentelimab (AK002) in patients with eosinophilic gastritis and/or eosinophilic duodenitis in the New England Journal of Medicine.All AK002 dose arms showed clinically meaningful and statistically significant benefits compared to placebo on all prespecified primary and secondary endpoints, including gastrointestinal tissue eosinophil counts and patient-reported disease symptoms.Last year, the company announced positive top line data from the study, demonstrating a 95% reduction in the number of eosinophils (a type of white blood cell associated with inflammation/infection) in gastrointestinal tissue compared to a 10% increase in the control group (p<0.0001). All secondary endpoints were also met.

For further details see:

Allakos's lirentelimab data published in New England Journal of Medicine